Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,931 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC; KIDCARE Multicenter Study Group; Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S. Roberts SC, et al. Among authors: chatterjee a. Contemp Clin Trials. 2019 Apr;79:98-103. doi: 10.1016/j.cct.2019.02.008. Epub 2019 Mar 3. Contemp Clin Trials. 2019. PMID: 30840903 Free article.
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S; KIDCARE Multicenter Study Group. Burns JC, et al. Lancet Child Adolesc Health. 2021 Dec;5(12):852-861. doi: 10.1016/S2352-4642(21)00270-4. Epub 2021 Oct 27. Lancet Child Adolesc Health. 2021. PMID: 34715057 Free article. Clinical Trial.
Epidemiological and Clinical Features of Kawasaki Disease During the COVID-19 Pandemic in the United States.
Burney JA, Roberts SC, DeHaan LL, Shimizu C, Bainto EV, Newburger JW, Dominguez S, Jone PN, Jaggi P, Szmuszkovicz JR, Rowley AH, Samuy N, Scalici P, Tremoulet AH, Cayan DR, Burns JC; KIDCARE Study Investigators. Burney JA, et al. JAMA Netw Open. 2022 Jun 1;5(6):e2217436. doi: 10.1001/jamanetworkopen.2022.17436. JAMA Netw Open. 2022. PMID: 35713905 Free PMC article.
Recurrent midline frontal mass in a patient with sinusitis.
Patel SA, Chatterjee A, Simonsen K. Patel SA, et al. Among authors: chatterjee a. Clin Pediatr (Phila). 2011 Mar;50(3):266-8. doi: 10.1177/0009922809352680. Epub 2010 Jan 28. Clin Pediatr (Phila). 2011. PMID: 20118095 No abstract available.
Lemierre-like syndrome: a series of unique cases.
Hoffman MA, Birge ND, Chatterjee A, Cavalieri SJ, Akhtar JI, Cornish NE, Truemper EJ, Varman M. Hoffman MA, et al. Among authors: chatterjee a. Clin Pediatr (Phila). 2010 Sep;49(9):893-6. doi: 10.1177/0009922810366733. Epub 2010 May 19. Clin Pediatr (Phila). 2010. PMID: 20488807 No abstract available.
Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers: a randomized, controlled, open-label, multicenter study.
Chatterjee A, O'Keefe C, Varman M, Klein NP, Luber S, Tomovici A, Noriega F. Chatterjee A, et al. Vaccine. 2012 May 14;30(23):3360-8. doi: 10.1016/j.vaccine.2012.03.057. Epub 2012 Apr 1. Vaccine. 2012. PMID: 22475857 Clinical Trial.
3,931 results